Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease (original) (raw)
Article navigation
Research Articles| August 19 1998
Maria Eriksdotter Jönhagen
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
b Department of Developmental Neuroscience, Uppsala University, Biomedical Center, Uppsala,
Search for other works by this author on:
c Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Karolinska Hospital, Stockholm,
Search for other works by this author on:
d Department of Neuroscience, Karolinska Institute, Stockholm, and
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
f Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan
Search for other works by this author on:
e Department of Clinical Chemistry, University Hospital, Linköping, Sweden;
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
a Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge,
Search for other works by this author on:
Dement Geriatr Cogn Disord (1998) 9 (5): 246–257.
Citation
Maria Eriksdotter Jönhagen, Agneta Nordberg, Kaarina Amberla, Lars Bäckman, Ted Ebendal, Björn Meyerson, Lars Olson, Åke Seiger, Masahiro Shigeta, Elvar Theodorsson, Matti Viitanen, Bengt Winblad, Lars-Olof Wahlund; Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease. _Dement Geriatr Cogn Disord 1 October 1998; 9 (5): 246–257. https://doi.org/10.1159/000017069
Download citation file:
Abstract
Nerve growth factor (NGF) is important for the survival and maintenance of central cholinergic neurons, a signalling system impaired in Alzheimer’s disease. We have treated 3 patients with Alzheimer’s disease with a total of 6.6 mg NGF administered continuously into the lateral cerebral ventricle for 3 months in the first 2 patients and a total of 0.55 mg for 3 shorter periods in the third patient. The patients were extensively evaluated with clinical, neuropsychological, neurophysiological and neuroradiological techniques. Three months after the NGF treatment ended, a significant increase in nicotine binding was found in several brain areas in the first 2 patients and in the hippocampus in the third patient as studied by positron emission tomography. A clear cognitive amelioration could not be demonstrated, although a few neuropsychology tests showed slight improvements. The amount of slow-wave cortical activity as studied by electroencephalography was reduced in the first 2 patients. Two negative side effects occurred with NGF treatment: first, a dull, constant back pain was observed in all 3 patients, which in 1 patient was aggravated by axial loading resulting in sharp, shooting pain of short duration. When stopping the NGF infusion, the pain disappeared within a couple of days. Reducing the dose of NGF lessened the pain. Secondly, a marked weight reduction during the infusion with a clear weight gain after ending the infusion was seen in the first 2 patients. We conclude from this limited trial that, while long-term intracerebroventricular NGF administration may cause certain potentially beneficial effects, the intraventricular route of administration is also associated with negative side effects that appear to outweigh the positive effects of the present protocol. Alternative routes of administration, and/or lower doses of NGF, perhaps combined with low doses of other neurotrophic factors, may shift this balance in favor of positive effects.
This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 